Maurits Wondergem1,2, Friso M van der Zant3, Remco J J Knol3, Sergiy V Lazarenko3, Jan Pruim4,5, Igle J de Jong2. 1. Department of Nuclear Medicine, Noordwest Ziekenhuisgroep locatie Alkmaar, Alkmaar, The Netherlands M.Wondergem@nwz.nl. 2. Department of Urology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 3. Department of Nuclear Medicine, Noordwest Ziekenhuisgroep locatie Alkmaar, Alkmaar, The Netherlands. 4. Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; and. 5. Department of Nuclear Medicine, Tygerberg Hospital, Stellenbosch University, Stellenbosch, South Africa.
Abstract
There is increasing interest in PET/CT with prostate-specific membrane antigen (PSMA) tracers for imaging of prostate cancer because of the higher detection rates of prostate cancer lesions than with PET/CT with choline. For 68Ga-PSMA-11 tracers, late imaging at 180 min after injection instead of imaging at 45-60 min after injection improves the detection of prostate cancer lesions. For 18F-DCFPyL, improved detection rates have recently been reported in a small pilot study. In this study, we report the effects of PET/CT imaging at 120 min after injection of 18F-DCFPyL in comparison to images acquired at 60 min after injection in a larger clinical cohort of 66 consecutive patients with histopathologically proven prostate cancer. Methods: Images were acquired 60 and 120 min after injection of 18F-DCFPyL. We report the positive lesions specified for anatomic locations (prostate, seminal vesicles, local lymph nodes, distant lymph nodes, bone, and others) at both time points by visual analysis, the image quality at both time points, and a semiquantitative analysis of the tracer activity in both prostate cancer lesions as well as normal tissues at both time points. Results: Our data showed a significantly increasing uptake of 18F-DCFPyL between 60 and 120 min after injection in 203 lesions characteristic for prostate cancer (median, 10.78 vs. 12.86, P < 0.001, Wilcoxon signed-rank test). By visual analysis, 38.5% of all patients showed more lesions using images at 120 min after injection than using images at 60 min after injection, and in 9.2% a change in TNM staging was found. All lesions seen on images 60 min after injection were also visible on images 120 min after injection. A significantly better mean signal-to-noise ratio of 11.93 was found for images acquired 120 min after injection (P < 0.001, paired t test; signal-to-noise ratio at 60 min after injection, 11.15). Conclusion: 18F-DCFPyL PET/CT images at 120 min after injection yield a higher detection rate of prostate cancer characteristic lesions than images at 60 min after injection. Further studies are needed to elucidate the best imaging time point for 18F-DCFPyL.
There is increasing interest in PET/CT with prostate-specific membrane antigen (PSMA) tracers for imaging of prostate cancer because of the higher detection rates of prostate cancer lesions than with PET/CT with choline. For 68Ga-PSMA-11 tracers, late imaging at 180 min after injection instead of imaging at 45-60 min after injection improves the detection of prostate cancer lesions. For 18F-DCFPyL, improved detection rates have recently been reported in a small pilot study. In this study, we report the effects of PET/CT imaging at 120 min after injection of 18F-DCFPyL in comparison to images acquired at 60 min after injection in a larger clinical cohort of 66 consecutive patients with histopathologically proven prostate cancer. Methods: Images were acquired 60 and 120 min after injection of 18F-DCFPyL. We report the positive lesions specified for anatomic locations (prostate, seminal vesicles, local lymph nodes, distant lymph nodes, bone, and others) at both time points by visual analysis, the image quality at both time points, and a semiquantitative analysis of the tracer activity in both prostate cancer lesions as well as normal tissues at both time points. Results: Our data showed a significantly increasing uptake of 18F-DCFPyL between 60 and 120 min after injection in 203 lesions characteristic for prostate cancer (median, 10.78 vs. 12.86, P < 0.001, Wilcoxon signed-rank test). By visual analysis, 38.5% of all patients showed more lesions using images at 120 min after injection than using images at 60 min after injection, and in 9.2% a change in TNM staging was found. All lesions seen on images 60 min after injection were also visible on images 120 min after injection. A significantly better mean signal-to-noise ratio of 11.93 was found for images acquired 120 min after injection (P < 0.001, paired t test; signal-to-noise ratio at 60 min after injection, 11.15). Conclusion: 18F-DCFPyL PET/CT images at 120 min after injection yield a higher detection rate of prostate cancer characteristic lesions than images at 60 min after injection. Further studies are needed to elucidate the best imaging time point for 18F-DCFPyL.
Authors: Ali Afshar-Oromieh; Lars Peter Sattler; Katja Steiger; Tim Holland-Letz; Marcelo Livorsi da Cunha; Walter Mier; Oliver Neels; Klaus Kopka; Wilko Weichert; Uwe Haberkorn Journal: Eur J Nucl Med Mol Imaging Date: 2018-03-01 Impact factor: 9.236
Authors: Bernard H E Jansen; Gem M Kramer; Matthijs C F Cysouw; Maqsood M Yaqub; Bart de Keizer; Jules Lavalaye; Jan Booij; Hebert Alberto Vargas; Michael J Morris; André N Vis; Reindert J A van Moorselaar; Otto S Hoekstra; Ronald Boellaard; Daniela E Oprea-Lager Journal: J Nucl Med Date: 2019-01-10 Impact factor: 10.057
Authors: Boris D Zlatopolskiy; Heike Endepols; Philipp Krapf; Mehrab Guliyev; Elizaveta A Urusova; Raphael Richarz; Melanie Hohberg; Markus Dietlein; Alexander Drzezga; Bernd Neumaier Journal: J Nucl Med Date: 2018-11-02 Impact factor: 10.057
Authors: M Hohberg; C Kobe; P Täger; J Hammes; M Schmidt; F Dietlein; M Wild; A Heidenreich; A Drzezga; M Dietlein Journal: Mol Imaging Biol Date: 2019-06 Impact factor: 3.488
Authors: Etienne Rousseau; Don Wilson; Frédéric Lacroix-Poisson; Andra Krauze; Kim Chi; Martin Gleave; Michael McKenzie; Scott Tyldesley; S Larry Goldenberg; François Bénard Journal: J Nucl Med Date: 2019-04-12 Impact factor: 10.057
Authors: Rudolf A Werner; Thorsten Derlin; Constantin Lapa; Sara Sheikbahaei; Takahiro Higuchi; Frederik L Giesel; Spencer Behr; Alexander Drzezga; Hiroyuki Kimura; Andreas K Buck; Frank M Bengel; Martin G Pomper; Michael A Gorin; Steven P Rowe Journal: Theranostics Date: 2020-01-01 Impact factor: 11.556